Novacap completes th
Novacap completes the acquisition of PCI Synthesis and expands its pharmaceutical offerings in the U.S.
June 28, 2018 12:01 ET | PCI Synthesis; Novacap
LYON, France and NEWBURYPORT, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Novacap, a worldwide player in pharmaceutical synthesis and advanced specialties, announced today that it has completed the...
Novacap to expand it
Novacap to expand its pharmaceutical offering in the U.S. with the acquisition of PCI Synthesis
June 20, 2018 12:03 ET | PCI Synthesis; Novacap
LYON, France and NEWBURYPORT, Mass., June 20, 2018 (GLOBE NEWSWIRE) -- Novacap, a worldwide player in pharmaceutical synthesis and advanced specialties, announced today that it has signed an...
PCI Synthesis Celebr
PCI Synthesis Celebrates Key Milestones Including 4th Consecutive Year of Double-Digit Growth, 2 Commercial Approvals and a New Office in San Diego
February 27, 2018 09:15 ET | PCI Synthesis
NEWBURYPORT, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEis), generic active pharmaceutical...
PCI Synthesis Submit
PCI Synthesis Submits Patent for Synthesizing Azelaic Acid
January 30, 2018 09:15 ET | PCI Synthesis
NEWBURYPORT, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical...
PCI Synthesis’ Ed Pr
PCI Synthesis’ Ed Price Joins SOCMA’s Board of Governors
January 11, 2018 09:15 ET | PCI Synthesis
NEWBURYPORT, Mass., Jan. 11, 2018 (GLOBE NEWSWIRE) -- PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical...
PCI Synthesis Identi
PCI Synthesis Identifies Trends Affecting the Generic Drugs Sector in 2018
December 18, 2017 09:15 ET | PCI Synthesis
NEWBURYPORT, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical...
Scott VanderWel, Business Development Manager
Scott VanderWel Joins PCI Synthesis as Business Development Manager
November 15, 2017 10:15 ET | PCI Synthesis
NEWBURYPORT, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) --  PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical...
PCI Synthesis Wins Big at 2017 Life Science Leader Magazine CMO Leadership Awards
March 23, 2017 09:14 ET | PCI Synthesis
NEWBURYPORT, MA--(Marketwired - Mar 23, 2017) - PCI Synthesis, Inc., a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other...
PCI Synthesis picks up Life Science CMO Leaderships Awards in all six categories
February 01, 2017 09:11 ET | PCI Synthesis
NEWBURYPORT, MA--(Marketwired - Feb 1, 2017) - PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients...
PCI Synthesis Identifies Trends Affecting the Generic Drugs Sector in 2017
December 19, 2016 09:16 ET | PCI Synthesis
NEWBURYPORT, MA--(Marketwired - Dec 19, 2016) - PCI Synthesis, Inc. (www.pcisynthesis.com), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients...